1. Home
  2. TTRX vs JELD Comparison

TTRX vs JELD Comparison

Compare TTRX & JELD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$9.43

Market Cap

281.2M

Sector

Health Care

ML Signal

HOLD

Logo JELD-WEN Holding Inc.

JELD

JELD-WEN Holding Inc.

HOLD

Current Price

$1.22

Market Cap

152.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTRX
JELD
Founded
2015
1960
Country
United States
United States
Employees
2
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Forest Products
Sector
Health Care
Basic Materials
Exchange
Nasdaq
Nasdaq
Market Cap
281.2M
152.5M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
TTRX
JELD
Price
$9.43
$1.22
Analyst Decision
Strong Buy
Hold
Analyst Count
1
6
Target Price
$8.00
$3.43
AVG Volume (30 Days)
99.8K
1.8M
Earning Date
05-31-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,211,181,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$0.93
52 Week High
$11.69
$6.98

Technical Indicators

Market Signals
Indicator
TTRX
JELD
Relative Strength Index (RSI) 72.19 37.42
Support Level $4.40 $0.93
Resistance Level N/A $2.06
Average True Range (ATR) 1.01 0.17
MACD 0.20 -0.03
Stochastic Oscillator 63.17 9.15

Price Performance

Historical Comparison
TTRX
JELD

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

About JELD JELD-WEN Holding Inc.

JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.

Share on Social Networks: